Biomarker ID 2565 |
| Detailed information | |
|---|---|
| CancerLivER ID | 2565 |
| Biomarker | EphA2 |
| Biomarker Name/Symbol (given in Publication) | EphA2 |
| Biomolecule | Protein and RNAs |
| Subject | Human |
| Degree of Validity | Potential serum marker for the detection of HCC development and progression; but not validated on independent patients's cohort |
| Experimental Condition | HCC v/s non-tumor/normal; associated with the poor survival of patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in HCC |
| Level of significance | p < 0.05 |
| Source | Tissue and Seum |
| PMID | 19642143 |
| Type of Biomarker | Diagnostic and Prognostic |
| Pathway | Apoptosis |
| Cohort | Human hepatoma cell lines, including HepG2 cells, Hep3B cells, PLC/PRF/5 cells, SK-Hep-1 cells and Chang liver cells were obtained from the American Type Culture Collection (Rockville, MD). Human hepatoma cell lines, including SH- J1 cells, HLK3 cells, HKK2 cells and HLK5 cells, were estab- lished f |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCC v/s non-tumor/normal |
| Year of Publication | 2010 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |